| DNA-repair defects and olaparib in metastatic prostate cancer J Mateo, S Carreira, S Sandhu, S Miranda, H Mossop, R Perez-Lopez, ... New England Journal of Medicine 373 (18), 1697-1708, 2015 | 2407 | 2015 |
| Genomic correlates of clinical outcome in advanced prostate cancer W Abida, J Cyrta, G Heller, D Prandi, J Armenia, I Coleman, M Cieslik, ... Proceedings of the National Academy of Sciences 116 (23), 11428-11436, 2019 | 1201 | 2019 |
| Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial J Mateo, N Porta, D Bianchini, U McGovern, T Elliott, R Jones, I Syndikus, ... The Lancet Oncology 21 (1), 162-174, 2020 | 630 | 2020 |
| Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition J Goodall, J Mateo, W Yuan, H Mossop, N Porta, S Miranda, ... Cancer discovery 7 (9), 1006-1017, 2017 | 415 | 2017 |
| Tumor clone dynamics in lethal prostate cancer S Carreira, A Romanel, J Goodall, E Grist, R Ferraldeschi, S Miranda, ... Science translational medicine 6 (254), 254ra125-254ra125, 2014 | 402 | 2014 |
| Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer A Paschalis, B Sheehan, R Riisnaes, DN Rodrigues, B Gurel, C Bertan, ... European urology 76 (4), 469-478, 2019 | 401 | 2019 |
| Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor LJ Barber, S Sandhu, L Chen, J Campbell, I Kozarewa, K Fenwick, ... The Journal of pathology 229 (3), 422-429, 2013 | 398 | 2013 |
| Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer A Sharp, I Coleman, W Yuan, C Sprenger, D Dolling, DN Rodrigues, ... The Journal of clinical investigation 129 (1), 192-208, 2019 | 385 | 2019 |
| IL-23 secreted by myeloid cells drives castration-resistant prostate cancer A Calcinotto, C Spataro, E Zagato, D Di Mitri, V Gil, M Crespo, ... Nature 559 (7714), 363-369, 2018 | 368 | 2018 |
| Randomized phase II study evaluating Akt blockade with ipatasertib, in combination with abiraterone, in patients with metastatic prostate cancer with and without PTEN loss JS de Bono, U De Giorgi, DN Rodrigues, C Massard, S Bracarda, A Font, ... Clinical Cancer Research 25 (3), 928-936, 2019 | 317 | 2019 |
| PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate R Ferraldeschi, DN Rodrigues, R Riisnaes, S Miranda, I Figueiredo, ... European urology 67 (4), 795-802, 2015 | 288 | 2015 |
| Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer E Ruark, K Snape, P Humburg, C Loveday, I Bajrami, R Brough, ... Nature 493 (7432), 406-410, 2013 | 281 | 2013 |
| Genomics of lethal prostate cancer at diagnosis and castration resistance J Mateo, G Seed, C Bertan, P Rescigno, D Dolling, I Figueiredo, ... The Journal of clinical investigation 130 (4), 1743-1751, 2020 | 268 | 2020 |
| Visceral disease in castration-resistant prostate cancer CJ Pezaro, A Omlin, D Lorente, DN Rodrigues, R Ferraldeschi, ... European urology 65 (2), 270-273, 2014 | 254 | 2014 |
| Phosphorylated RB promotes cancer immunity by inhibiting NF-κB activation and PD-L1 expression X Jin, D Ding, Y Yan, H Li, B Wang, L Ma, Z Ye, T Ma, Q Wu, ... Molecular cell 73 (1), 22-35. e6, 2019 | 227 | 2019 |
| Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer DN Rodrigues, P Rescigno, D Liu, W Yuan, S Carreira, MB Lambros, ... The Journal of clinical investigation 128 (10), 4441-4453, 2018 | 225 | 2018 |
| Phase I trial of first-in-class ATR inhibitor M6620 (VX-970) as monotherapy or in combination with carboplatin in patients with advanced solid tumors TA Yap, B O’Carrigan, MS Penney, JS Lim, JS Brown, ... Journal of Clinical Oncology 38 (27), 3195-3204, 2020 | 218 | 2020 |
| Serial next-generation sequencing of circulating cell-free DNA evaluating tumor clone response to molecularly targeted drug administration JS Frenel, S Carreira, J Goodall, D Roda, R Perez-Lopez, N Tunariu, ... Clinical Cancer Research 21 (20), 4586-4596, 2015 | 211 | 2015 |
| Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra‐tumour genetic heterogeneity and clonal … L Hernandez, PM Wilkerson, MB Lambros, A Campion‐Flora, ... The Journal of pathology 227 (1), 42-52, 2012 | 201 | 2012 |
| Nrf2 as a potential mediator of cardiovascular risk in metabolic diseases RM da Costa, D Rodrigues, CA Pereira, JF Silva, JV Alves, NS Lobato, ... Frontiers in Pharmacology 10, 382, 2019 | 163 | 2019 |
Johann de BonoInstitute of Cancer ResearchVerified email at icr.ac.uk